Answer
No, there is no relevant use of amivantamab in the paediatric population for treating non-small cell lung cancer.
Sources for this answer
- Rybrevant (amivantamab) 350mg concentrate for solution for infusionJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.2 Posology and method of administration · Version 11Document updated
Sources checked